Advanced malignant tumors
Conditions
Interventions
Every patient included will be prescribed with 5 sublingual drops of Vidatox 30CH homeopathic drug, 3 times per day during 6 months. After 6 months of treatment their quality of life will be evaluated
Sponsors
Enterprise Group of Biopharmaceutic and Chemical Productions LABIOFAM
Eligibility
Sex/Gender
All
Age
19 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients with histological diagnose of malignant tumors in IIIb and IV stages 19 years old or older patients Patients capable to anwser questionaries Patients with written consens to participate in the study
Exclusion criteria
Exclusion criteria: Pregnancy or breast feeding Patients included in another clinical trial Patients treated with Vidatox® 30CH one month before starting the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quality of life (EORTC QLQ-C30 quality of life questionnaire). Measuring time: at baseline and monthly until 12 months of treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events (AE). Measuring time: Monthly until 12 months of treatment. -Description of AE (Name of the event) -Duration of AE (Difference between the beginning date and the finish date of the event) -Intensity of AE (Light , Moderate, Severe) -Severity of AE (Severe/Serious,Not severe/Not serious) -Attitude to study treatment (Unchanged,Dose modification ,Temporary discontinuation of study treatment,Permanent discontinuation of study treatment) -Outcome of AE (Recovered,Improved,Persist,Persist,Sequelae) -Relationship causality (Definitive,Very likely,Probable,Possible,Not related,Unknown) | — |
Countries
Cuba
Contacts
Public ContactCarmen Morales Paneque
Clinical Trials Division, Enterprise Group LABIOFAM
Outcome results
None listed